Beyond 18F-fluorodeoxyglucose: Making the next generation of PET radiotracers available for oncology research in the UK

Nuclear Medicine Communications

Volumn 32, Issue 1, 2011, Pages 1-3

  Gilbert, Fiona Jane ^a,c   Fleming, Ian N ^a,c   Marsden, Paul K ^b,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c National Cancer Research Institute   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3 FLUORO 2 ( 4 (( 2 NITRO 1H IMIDAZOL 1 YL)METHYL) 1H 1,2,3 TRIAZOL 1 YL)PROPAN 1 OL F 18; 3' FLUOROTHYMIDINE F 18; DIACETYL BIS(N 4 METHYLTHIOSEMICARBAZONE) CU 64; FLUORODEOXYGLUCOSE F 18; GE 135 F 18; ML 10 F 18; TRACER; UNCLASSIFIED DRUG;

CANCER RESEARCH; EDITORIAL; HUMAN; MEDICAL SOCIETY; POSITRON EMISSION TOMOGRAPHY; UNITED KINGDOM;

BIOMEDICAL RESEARCH; FLUORODEOXYGLUCOSE F18; GREAT BRITAIN; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS;

EID: 78650312842     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283406acf     Document Type: Editorial

References (6)

1. 18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979; 44:127-137 (Pubitemid 9089586)
2. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124:269-270.
3. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42 (5 Suppl):1S-93S.
4. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 2007; 11:iii-iv, xi-267.
5. 18F]FDG PET in clinical oncology. Lancet Oncol 2007; 8:822-830.
6. Murphy PS, Bergström M. Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective. Curr Pharm Des 2009; 15:957-965.